Compare Firy Inc. (FIRY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Mesoblast Limited — how do they compare? Firy Inc. trades at $11.9 (market cap $199.80M), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Mesoblast Limited is far larger — about 8.8× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Mesoblast Limited for 14 Days on average.
| FIRY | MESO | |
|---|---|---|
Market Cap | $199.80M | $1.75B |
Volume | 92,993 | 239,027 |
Sector | Technology | Health |
52-Week High | $13.10 | $20.96 |
52-Week Low | $2.28 | $13.19 |
Typical Hold Time | 13 Days | 14 Days |
Enterprise Value | $168.40M | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY (formerly Skillz Inc.) trades at $11.85, down 5.05% today, with a bullish technical signal from moving averages despite negative fundamental metrics. The company reported Q2 2026 revenue of $31.0 million but missed EPS expectations with a net loss. Recent developments include a $719 million legal victory against Papaya Gaming and the appointment of Marc Lasry to the board, though cash burn remains elevated at -$86.41M for 2025.
The outlook remains challenged by persistent losses and negative margins, but potential collection of the legal judgment could provide significant upside. Risks include execution on cost controls and uncertainty around Papaya Gaming debt settlement. Analyst sentiment is mixed with 20% buy ratings amid high volatility.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
